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Claudin-2, a component  
of the tight junction, forms  
a paracellular water channel
Rosenthal et al., J Cell Sci 2010; 123: 1913–1921; doi:10.1242/jcs.060665
The proximal tubule, like the small intestine, is a ‘leaky epithe-
lium,’ characterized by high rates of ions and water transport 
and inability to maintain steep osmotic and electrical gradients. 
Although it has been established for several years that ions pass 
these epithelia via both transcellular and paracellular pathways, 
the exact mechanism of water transport is unclear. The seminal 
discovery of aquaporins (AQPs) as water channels in epithelial 
cell membranes made clear that water moves along a transcellu-
lar pathway. However, the contribution of the paracellular water 
movement through the tight junctions (TJs) has been estimated 
to be between 0 and 100%, depending on the method used for 
analysis. Moreover, although TJs are often called aqueous pores, 
there has not yet been direct experimental evidence of paracel-
lular water flux, because of a variety of technical difficulties. To 
demonstrate paracellular water transport, Rosenthal et al. selec-
tively changed the molecular composition of the TJ so that it 
would alter ion permeability and measured overall transepithelial 
water flux before and after the change.
TJs are composed of several transmembrane proteins, including 
occludin and members of the claudin family. The barrier proper-
ties of TJs vary dramatically, depending mainly on the tissue- and 
segment-specific expression of claudins, with some claudins sup-
porting the epithelial barrier function and others forming paracel-
lular channels. For example, the expression of claudin-2 is typical 
of leaky epithelia such as the proximal tubule, where it forms 
a cation-selective channel. By contrast, claudin-10b, while also 
mediating permeability to small monovalent cations, is expressed 
in many epithelial tissues, including segments of Henle’s loop 
that are impermeable to water. The MDCK C7 cell line does not 
endogenously express either claudin-2 or claudin-10b, and when 
it forms a monolayer, it is a “tight” epithelium.
Rosenthal et al. stably transfected MDCK C7 cells with either 
claudin-2 or claudin-10b (Figure) and found that neither transfec-
tion altered the expression of endogenous claudins or aquaporins. 
When they induced water flux by an osmotic gradient, a Na+ 
gradient, or both, they found that—under all conditions—water 
flux in claudin-2-transfected cells was elevated compared with 
vector controls, indicating claudin-2-mediated paracellular water 
permeability. Because Na+-driven water transport occurred in the 
absence of an osmotic gradient, the movement occurred through a 
single-file mechanism. In marked contrast, claudin-10b transfec-
tion did not alter water flux. The study thus shows that claudin-2, 
but not claudin-10b, forms a paracellular water channel and thus 
mediates paracellular water transport in leaky epithelia.
Juan Oliver
Rituximab versus 
cyclophosphamide in ANCA-
associated renal vasculitis
Jones et al., N Engl J Med 2010; 363: 211–220; doi:10.1056/NEJMe1004992
This trial assessed the treatment response and rates of associated 
severe adverse events of a rituximab-based regimen, as com-
pared with one based on cyclophosphamide, in the induction of 
patients with recently diagnosed severe vasculitis associated with 
antineutrophil cytoplasmic autoantibodies (ANCAs). To address 
the need to characterize the safety of rituximab, 44 patients from 
eight centers with newly diagnosed ANCA-associated vasculitis 
were randomized in a 3:1 ratio of rituximab versus cyclosporine. 
After randomization, all patients received 1 g of methylpred-
nisolone and 1 mg/kg of oral glucocorticoids daily. The oral 
glucocorticoid dose was reduced to 5 mg/day after 6 months. 
Patients randomized to rituximab received 375 mg/meter2 per 
week of rituximab for 4 consecutive weeks and intravenous 
cyclophosphamide (15 mg/kg with the first and third rituximab 
infusions) but did not receive azathioprine. Patients in the control 
group received intravenous cyclophosphamide for 3–6 months 
followed by azathioprine. Primary outcomes were sustained for 
remission and rates of severe adverse events at 12 months.
Sustained remission occurred in 76% of patients in the rituxi-
mab group and 82% of patients in the control group. Six patients 
in the rituximab group and one patient in the controlled group 
died within the first 12 months. The median time to remission 
was 90 days in the rituximab group and 94 days in the control 
group. Forty-two percent of patients in the rituximab group and 
36% of patients in the control group experienced severe adverse 
events, with incident rates of 1.00/patient-year in the rituximab 
group and 1.10/patient-year in the control group. Thirty-six 
percent of patients in the rituximab group and 27% of patients 
in the control group experienced infections. Mean estimated 
Subcellular distribution of transfected claudins. Immunofluorescence 
staining of (a) claudin-2 (red) and (b) claudin-10 (red) together 
with occludin (green) in transfected MDCK C7 cells demonstrates 
colocalization (yellow) of the claudins with the TJ marker occludin.
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glomerular filtration rate increased from 20 to 39 ml/min in the 
rituximab group and from 12 to 27 ml/min in the control group 
at 12 months. While there was no difference in changes in score 
in the physical components of the Short Form–36 Health Survey 
between the groups, the control group had better outcomes in the 
mental components. However, the authors attribute this finding 
to two influential outliers in the rituximab group.
The important limitation of power of the study should be con-
sidered. While these data do not support a difference of more 
than 33% between regimens in efficacy, they cannot establish 
the equivalence of the two regimens. This trial does not have 
the ability to distinguish between small differences in efficacy 
or larger differences in safety. However, it provides supportive 
evidence for the use of rituximab in treatment-naive patients with 
ANCA-associated renal disease that needs to be considered on a 
case-by-case basis when choosing an initial therapy regimen.
Lynda Szczech
Gene for progression of FSGS  
renal disease in AA poulation: 
Exit MYH-9,enter APO L-1
Genovese et al., Science advance online publication, 15 July 2010, 
doi:10.1126/science.1193032
African-American (AA) individuals suffer from kidney failure 
at high rates compared with Americans of European ancestry. 
Two years ago, Kopp et al.1 and Kao et al.2 identified a region 
on chromosome 22 in African Americans with focal segmental 
glomerulosclerosis (FSGS), HIV nephropathy, or nondiabetic, 
hypertensive end-stage renal disease (ESRD) that contains 
noncoding single-nucleotide polymorphisms (SNPs) near the 
nonmuscle myosin heavy chain MYH9. These exciting observa-
tions led to a rush of experimental studies aiming to identify the 
potentially responsible mutations and gene(s). Although multiple 
genes were located in the original region, investigators focused 
on MYH9 because of its expression pattern and the fact that syn-
dromes with mutations in MYH9, such as Epstein’s and Fechtner’s 
syndromes, can present with renal disease. However, no causal 
mutations in MYH9 have been identified that would confer an 
increased risk for sporadic FSGS. The previous genome-wide 
analyses had, however, provided evidence that natural selection 
pressure results in a high prevalence in the AA population of 
the region containing the SNPs. The longer patterns of linkage 
disequilibrium in Africans in the chromosome 22 risk region led 
a group of investigators led by Martin Pollack to hypothesize that 
the region had been under selective pressure in Africa and that 
the kidney disease risk alleles might be located in a larger interval 
than originally thought. Such risk allele(s) would be likely to be 
common in people with African ancestry and would therefore 
be present in the data from the African individuals whose DNA 
was sequenced in the 1000 Genomes Project.
Using this newly available sequence data, Genovese et al. iden-
tified polymorphisms with large frequency differences between 
Africans and Europeans in this larger region and performed an 
initial association analysis comparing 205 AA individuals with 
biopsy-proven, sporadic FSGS with 180 AA controls. The strong-
est genetic associations with FSGS were clustered in a 10-kb 
region in the last exon of APOL1, the gene encoding apolipopro-
tein L-1. The strongest signal was obtained for two alleles—G1 
and G2—in the last exon of APOL1. The analysis of the risk 
provided by the G1 and G2 alleles supports a recessive pattern 
of inheritance in terms of renal disease. Next, the authors tested 
the association of APOL1 variants and renal disease in a larger 
cohort of 1,030 AA individuals with ESRD attributed to hyperten-
sion and in 1,025 geographically matched AA subjects. Again, 
the strongest association was with G1 and G2 mutations of the 
APOL1 gene. The statistical significance of the combined signal 
was 35 orders of magnitude stronger than for MYH9 SNPs. When 
the associations were controlled for both G1 and G2, no residual 
association remained for SNPs in MIYH9 after correction for 
multiple SNP testing. Analysis of the distribution of the alleles 
in various populations raised the possibility that these variants 
were selected for in Africa, but not outside of Africa. On the basis 
of these considerations, the authors looked for potential selection 
pressures that could have arisen in Africa. It is known that ApoL1 
is the trypanolytic factor of human serum that confers resistance to 
the Trypanosoma brucei brucei (T.b. brucei) parasite. T.b. brucei 
has evolved into two additional subspecies: Trypanosoma brucei 
rhodesiense and Trypanosoma brucei gambiense. In vitro assays 
revealed that only the kidney disease–associated ApoL1 variants 
lysed Trypanosoma brucei rhodesiense. The authors therefore 
speculate that evolution of this mutation with enhanced protec-
tion against T.b. rhodesiense provides a critical survival factor in 
Africa but may at the same time contribute to the high rates of 
renal disease in African Americans. Thus, the focus of interest 
shifts from MYH9 to sequence variations in APOL1 as contribu-
tors to the increased risk of renal disease in African Americans.
An important question to be addressed in future studies is how 
sequence variation in ApoL1 mechanistically contributes to the 
pathogenesis of kidney disease. The large body of information 
available about the role of ApoL1 in lysing trypanosomes may 
speed this research considerably. Cell-based in vitro assays with 
the mutations will be helpful, but, unfortunately, the ApoL1 
gene is restricted to primates and humans—transgenic mouse 
models containing the various isoforms of the human ApoL1 
will need to be generated for in vivo studies. Irrespective of 
this, these new and groundbreaking observations will provide 
us with unexpected directions into pathways leading to ESRD 
with glomerulosclerosis in the at-risk population with African 
ancestry. Furthermore, they could indicate crucial cell biological 
steps involved in maintaining normal glomerular anatomy and 
function. Finally, the paper documents the potential of genome-
sequencing data banks, such as the 1000 Genomes Project, in 
helping to identify genes contributing to specific diseases, an 
approach that will be further simplified by the next generation 
of sequencing technology. Conclusion and stage instructions: 
exit MYH9, enter ApoL1, and on with the identification of renal 
disease progression factors.
Detlef Schlöndorff
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